Diaccurate Announces the Appointment of Scott Filosi as CEO and Corporate Name Change to Evexta Bio
November 06, 2023 08:13 ET
|
DIACCURATE
Diaccurate Announces the Appointment of Scott Filosi as EVEXTA BIOCEO and Corporate Name Change to Evexta Bio Scott Filosi brings more than 30 years of experience in market access and...
Diaccurate présentera des données actualisées de son nouvel inhibiteur de la voie PAM DIACC3010 dans le cancer du sein métastatique ER+ HER2- à l’AACR 2023
April 06, 2023 08:30 ET
|
DIACCURATE
Diaccurate présentera des données actualisées de son nouvel inhibiteur de la voie PAM DIACC3010 dans le cancer du sein métastatique ER+ HER2- à l’AACR 2023 DIACC3010 a une excellente activité...
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023
April 06, 2023 08:30 ET
|
DIACCURATE
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023 DIACC3010 displays broad efficacy in...